Ignite Creation Date:
2024-05-05 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00116155
Status:
COMPLETED
Last Update Posted:
2005-06-28
First Post:
2005-06-27
Brief Title:
Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer
Sponsor:
Cell Genesys
Organization:
Cell Genesys
Study Overview
Official Title:
A Phase III Dose Finding Trial of the Intravenous Injection of CV787 a Prostate-Specific Antigen Cytolytic Adenovirus in Patients With Hormone Refractory Metastatic Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2005-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-center open-label dose finding study of CV787 adenovirus in patients with hormone refractory metastatic prostate cancer Patients will receive treatment intravenously at one of up to nine dose levels each containing three to six patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None